BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1634 related articles for article (PubMed ID: 32428386)

  • 1. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
    Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
    JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration.
    Manhapra A; Quinones L; Rosenheck R
    Drug Alcohol Depend; 2016 Mar; 160():82-9. PubMed ID: 26804898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.
    Rogal S; Youk A; Agbalajobi O; Zhang H; Gellad W; Fine MJ; Belperio P; Morgan T; Good CB; Kraemer K
    Am J Gastroenterol; 2021 Jul; 116(7):1406-1413. PubMed ID: 33811202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substance use disorders and the risk of suicide mortality among men and women in the US Veterans Health Administration.
    Bohnert KM; Ilgen MA; Louzon S; McCarthy JF; Katz IR
    Addiction; 2017 Jul; 112(7):1193-1201. PubMed ID: 28301070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
    Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
    J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary care experiences of veterans with opioid use disorder in the Veterans Health Administration.
    Jones AL; Kertesz SG; Hausmann LRM; Mor MK; Suo Y; Pettey WBP; Schaefer JH; Gundlapalli AV; Gordon AJ
    J Subst Abuse Treat; 2020 Jun; 113():107996. PubMed ID: 32359670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with clinician treatment recommendations for patients with a new diagnosis of opioid use disorder.
    Lin LA; Powell VD; Macleod C; Bohnert ASB; Lagisetty P
    J Subst Abuse Treat; 2022 Oct; 141():108827. PubMed ID: 35863212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?
    Manhapra A; Stefanovics E; Rosenheck R
    Subst Abus; 2020; 41(1):110-120. PubMed ID: 31403914
    [No Abstract]   [Full Text] [Related]  

  • 12. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities.
    Hagedorn H; Kenny M; Gordon AJ; Ackland PE; Noorbaloochi S; Yu W; Harris AHS
    Addict Sci Clin Pract; 2018 Dec; 13(1):25. PubMed ID: 30545409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care.
    Hawkins EJ; Malte CA; Hagedorn HJ; Gordon AJ; Williams EC; Trim RS; Blanchard BE; Lott A; Danner AN; Saxon AJ
    J Addict Med; 2024 May-Jun 01; 18(3):240-247. PubMed ID: 38329814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients.
    Finlay AK; Harris AH; Rosenthal J; Blue-Howells J; Clark S; McGuire J; Timko C; Frayne SM; Smelson D; Oliva E; Binswanger I
    Drug Alcohol Depend; 2016 Mar; 160():222-6. PubMed ID: 26832998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
    Schiff DM; Nielsen T; Hoeppner BB; Terplan M; Hansen H; Bernson D; Diop H; Bharel M; Krans EE; Selk S; Kelly JF; Wilens TE; Taveras EM
    JAMA Netw Open; 2020 May; 3(5):e205734. PubMed ID: 32453384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration.
    Ching JH; Owens DK; Trafton JA; Goldhaber-Fiebert JD; Salomon JA
    Addiction; 2021 Dec; 116(12):3494-3503. PubMed ID: 33999485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration.
    Kelly MM; Reilly E; Quiñones T; Desai N; Rosenheck R
    Drug Alcohol Depend; 2018 Feb; 183():111-117. PubMed ID: 29245103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs.
    Finlay AK; Wong JJ; Ellerbe LS; Rubinsky A; Gupta S; Bowe TR; Schmidt EM; Timko C; Burden JL; Harris AHS
    J Stud Alcohol Drugs; 2018 Nov; 79(6):909-917. PubMed ID: 30573022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlates of specialty substance use treatment among adults with opioid use disorders.
    Romo E; Ulbricht CM; Clark RE; Lapane KL
    Addict Behav; 2018 Nov; 86():96-103. PubMed ID: 29551551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 82.